⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413210 | 1.00 | — | — | |
| SCHEMBL3674005 | 0.86 | CHEK1 (0.44) | — | |
| SCHEMBL2013423 | 0.77 | PIK3CD (0.42) | — | |
| SCHEMBL933680 | 0.76 | — | — | |
| SCHEMBL24942539 | 0.74 | CHEK1 (0.38) | — | |
| SCHEMBL9991127 | 0.74 | — | — | |
| SCHEMBL30939702 | 0.74 | — | — | |
| SCHEMBL2011764 | 0.73 | PIK3CD (0.52) | — | |
| SCHEMBL21663747 | 0.72 | — | — | |
| SCHEMBL305290 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3898646-B1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260035375-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-12534451-B2 | Small molecule modulators of PanK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-22 | — | — | US | disclosed |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-12-09 | — | — | US | disclosed |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| CN-1305852-C | Diaryl ethers as opioid receptor antagonists | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| CN-1681498-A | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004026305-A9 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-0182111-B1 | PROCESS FOR THE PREPARATION OF PERHALOGENATED COMPOUNDS | BASF Aktiengesellschaft (DE) | 1989-09-20 | — | — | EP | disclosed |
| EP-0182111-A1 | Process for the preparation of perhalogenated compounds | BASF Aktiengesellschaft (DE) | 1986-05-28 | — | — | EP | disclosed |
| EP-0003562-B1 | PROCESS FOR THE PREPARATION OF HYDROXYPHENYL ETHERS | BAYER AG (DE) | 1981-07-08 | — | — | EP | disclosed |
| US-4264769-A | BY REACTING A DIHYDROXYBENZENE WITH A HETEROCYCLIC OR PHENYL HALIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-28 | — | — | US | disclosed |